TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC BioPharm (NASDAQ: TCBP) has rescheduled its shareholder update call to February 21, 2023, at 12:00 p.m. ET. Originally set for February 20, the call will cover the company's clinical trial plans for gamma-delta T cell therapies in oncology.

Management will provide insights into the company's 2023 outlook and discuss ongoing business development efforts. A Q&A session will follow the opening remarks, allowing investors to submit pre-recorded questions.

TC Biopharm (NASDAQ: TCBP, TCBPW) announced the completion of dosing its final patient in the safety cohort for the phase 2B trial of OmnImmune (TCB008) aimed at treating Acute Myeloid Leukemia (AML).

The trial transition from donor matching to a universal donor model is a significant advancement. The company anticipates a positive review from the Data Safety Monitoring Board (DSMB) in February, enabling open enrollment for 37 patients.

CEO Bryan Kobel expressed confidence in the trial's progress, highlighting recruitment success and upcoming interim reviews to assess dose levels, projecting significant market potential as the global AML market is expected to reach $2.6 billion by 2027.

The acute myeloid leukemia (AML) pipeline is experiencing significant growth, with over 200 companies developing more than 260 pipeline therapies. Notable companies include GlycoMimetics, Takeda Oncology, and TC Biopharm. The report emphasizes the advancement of novel therapies, such as Uproleselan and Pevonedistat, which are in various stages of development including Phase III trials. Additionally, recent designations like orphan drug status from the FDA for AML treatments highlight the urgency in addressing this prevalent disease. The comprehensive analysis covers the therapeutic landscape, including mechanisms of action and routes of administration.

TC BioPharm has appointed Bree Harlin as the new Chief Clinical Officer, effective immediately. With over 20 years of experience in oncology and clinical development, Harlin previously worked at Loxo at Lilly. Her expertise will be crucial as the company aims to expand its clinical trials in the U.S. and submit its first Investigational New Drug (IND) application in the latter half of 2023. TC BioPharm focuses on gamma-delta T cell therapies for cancer treatment and is recognized for its pivotal clinical studies. The company is positioned for growth as it develops its pipeline for various cancer indications.

TC BioPharm, a clinical-stage biotechnology company, will hold a shareholder update call on February 20, 2023, at 10:00 am ET. The meeting will focus on the company's clinical trial plan for allogeneic gamma-delta T cell therapies for cancer, including updates on its ongoing studies for acute myeloid leukemia and future oncology indications. CEO Bryan Kobel and CFO Martin Thorp will lead the call, which will include a Q&A session addressing pre-submitted questions from investors. Interested parties can join via the provided live call numbers or webcast link.

TC Biopharm (NASDAQ: TCBP) has received notice from Nasdaq stating that it has not met the minimum Market Value of Listed Securities (MVLS) of $35 million required for continued listing. The company plans to request a hearing to stay any suspension or delisting, presenting a compliance plan to address the MVLS deficiency. This notification does not immediately affect trading on Nasdaq, and the company’s ADSs and Warrants will continue to be listed while awaiting the panel's decision. Previously, TC Biopharm was given until January 11, 2023, to regain compliance after a July 2022 notice.

TC Biopharm, a clinical-stage biotechnology company, has announced a strategic collaboration with The University of Texas MD Anderson Cancer Center as of January 17, 2023. This partnership aims to enhance understanding of gamma-delta T cells for cancer treatment over a three-year period. The collaboration will harness MD Anderson's clinical trial infrastructure alongside TC Biopharm's gamma-delta T cell oncology pipeline, focusing on preclinical and clinical studies. The initiative is expected to yield insights that will refine future studies and aid in the development of new cancer therapies, particularly in blood cancers and solid tumors.

TC BioPharm (NASDAQ: TCBP) announced significant developments in its clinical pipeline and financial performance. They have dosed the first three patients in a Phase 2b trial for OmnImmune®, a therapy for Acute Myeloid Leukemia (AML), which showed promising response rates in prior studies. Financially, the company reported a net income of £0.5 million ($0.6 million) for the first half of 2022, a turnaround from a £2.6 million loss in 2021. Cash reserves stand at £6.0 million ($7.3 million), bolstered by a recent PIPE financing of £6.0 million in November 2022.

TC BioPharm (Nasdaq: TCBP) has successfully closed a private placement, raising $7.35 million by issuing 1,470,000 American Depositary Shares (ADSs) at a price of $5.00 per ADS. This includes Series A and Series B warrants, both with an exercise price of $5.00. The funds will be used for general working capital. The offering was conducted under Regulation D, targeting accredited investors. TC BioPharm specializes in allogeneic gamma-delta T cell therapies for cancer treatment and is currently engaged in pivotal clinical trials.